Clinical Knowledge Summary: Chronic Kidney-Metabolic (CKM) Health (Longevity Medicine)

 

1. Scope

Terminology note: “CKM” is used here for the cardiovascular-kidney-metabolic (CKM) construct formalised by the American Heart Association and adopted in the 2026 AHA/ACC/ADA/ASN guideline. “Chronic kidney-metabolic health” is not an independent, separately validated nosological entity; the evidence base derives from the cardiovascular-kidney-metabolic literature, and cardiovascular outcomes are inseparable from it.[1][2]

What is covered:

– Longitudinal preservation of kidney and cardiometabolic health across the life course in adults attending a longevity/preventive clinic, as an adjunct to conventional primary and secondary care.

– Risk stratification and staging (CKM stages 0–4), guideline-directed pharmacotherapy (RAS inhibitors, SGLT2 inhibitors, GLP-1–based therapy, non-steroidal MRAs, lipid-lowering therapy), lifestyle intervention, monitoring and safety.

– Emerging/off-label “geroprotective” use of these and other agents (e.g. metformin, SGLT2 inhibitors used for longevity indications), clearly separated by evidence tier.

What is NOT covered:

– Management of established kidney failure, dialysis, transplantation, or acute kidney injury (specialist nephrology domains).

– Detailed dyslipidaemia and hypertension pharmacology (deferred to dedicated ACC/AHA and NICE guidance).[1]

– Paediatric CKM staging.

– Interventions with only preclinical or anecdotal support as primary recommendations (segregated to sections 2 and 10).

Positioning: Content is adjunctive to, and should not replace, guideline-directed care delivered by NICE/NHS or equivalent. UK regulatory status (MHRA/NICE) governs licensed use; several longevity applications discussed are off-label using peer-reviewed evidence.

2. Background and pathophysiology

Core construct. CKM syndrome describes the pathophysiological interplay among excess/dysfunctional adiposity, metabolic risk factors (hypertension, atherogenic dyslipidaemia, dysglycaemia), CKD and cardiovascular disease.[1][2] Visceral adiposity is positioned as the upstream driver, generating inflammation and insulin resistance with resulting multisystem injury.[1]

Staging (AHA/ACC).

– Stage 0: no CKM risk factors.

– Stage 1: excess/dysfunctional adiposity (± prediabetes).

– Stage 2: metabolic risk factors (hypertension, hypertriglyceridaemia, metabolic syndrome, diabetes) or CKD.

– Stage 3: subclinical CVD in CKM, or high predicted risk / very-high-risk CKD.

– Stage 4: clinical CVD in the setting of CKM.[1]

Longevity relevance. Advanced CKM stage is associated with substantial reductions in projected life expectancy in US cohort modelling, with losses of roughly 6–13 years at age 40 depending on subgroup — supporting early staging as a longevity intervention.[3] Staging is explicitly intended to enable stage regression through weight loss and lifestyle change.[1]

Mechanisms targeted (robust human evidence).

– Intraglomerular pressure and tubuloglomerular feedback: RAS inhibitors and SGLT2 inhibitors reduce intraglomerular hypertension; SGLT2 inhibitors cause a protective early eGFR “dip”.[4]

– Adiposity/insulin resistance: weight loss and incretin-based therapy reduce visceral fat, blood pressure, glycaemia and albuminuria.[4][5]

– Aldosterone-mediated inflammation/fibrosis: non-steroidal MRAs (finerenone) reduce fibrosis and inflammation with kidney and cardiovascular benefit.[4][6]

Preclinical / mechanistic-only subsection (NOT a basis for clinical recommendation).

– SGLT2 inhibitors induce a caloric-restriction/ketogenic-like state, attenuate inflammation, improve mitochondrial function and may reduce senescent-cell burden and modulate the senescence-associated secretory phenotype; lifespan extension has been shown in animal models but antiaging efficacy in humans is unproven.[7]

– Metformin affects AMPK, mTORC1, cellular senescence, autophagy and NF-κB, and extends lifespan in some animal models. This is mechanistic plausibility, not demonstrated human longevity benefit.[8][9]

– Caloric restriction, rapamycin/rapalogs and senolytics (dasatinib+quercetin, fisetin) act on autophagy, mTOR and senescent-cell burden in preclinical models; human data are early-phase or absent.[10][11]

3. Evidence base and grading

Types of evidence available. High-quality RCTs and meta-analyses exist for SGLT2 inhibitors, GLP-1 receptor agonists, finerenone and RAS inhibitors on hard kidney and cardiovascular outcomes; high-quality RCT meta-analysis for lifestyle weight loss and mortality; large multisociety guidelines; prospective cohorts for lifestyle/risk-factor control.[12][4][6][13][14][1][15][16][17][18] Geroprotective longevity applications rest largely on observational data, preclinical models and mechanistic reasoning.[11][7][9]

GRADE-style certainty and strength of recommendation for major outcomes:

Outcome / intervention	Certainty	Evidence statement	Strength of recommendation	References
SGLT2 inhibitors → slow CKD progression, kidney failure (diabetic + non-diabetic CKD)	High	Multiple large RCTs (DAPA-CKD, EMPA-KIDNEY, CREDENCE) and meta-analyses; ~57% slowing of eGFR decline vs untreated	Strong (guideline-based, on-label for CKD)	[4], [15], [19]
SGLT2 inhibitors → CV death / HF hospitalisation	High	Consistent across large CVOTs irrespective of diabetes	Strong	[4], [7]
GLP-1 RA → MACE, all-cause death	High	Meta-analysis incl. SELECT, FLOW; benefit consistent regardless of diabetes status	Strong (for indicated populations)	[12]
GLP-1 RA → kidney failure	Moderate	Meta-analysis significant; earlier signals largely driven by albuminuria	Conditional	[12]
Finerenone → CKD progression + CV events (CKD, broad)	High	INFINITY pooled IPD (3 RCTs, >14,000); benefit across glycaemic status and aetiology	Strong in CKD+T2D+albuminuria; Conditional beyond (off-label)	[6]
RAS inhibitors → slow CKD, reduce CV events in albuminuric CKD	High	Long-standing RCT evidence; STOP-ACEi shows no benefit to stopping	Strong	[4]
Intentional (lifestyle) weight loss → all-cause mortality in obesity	Moderate–High	RCT meta-analyses: RR ~0.82–0.85	Conditional–Strong	[13], [14]
Statins/LDL-lowering → ASCVD prevention in CKM	High	Established; targets by CKM stage/CAC	Strong	[1]
Metformin → mortality/age-related disease in people WITHOUT diabetes	Very low (for longevity claim)	DPPOS RCT: no mortality reduction over 21y; geroprotective claims observational/confounded; TAME/VA-IMPACT ongoing	Only in research	[9], [20]
SGLT2 inhibitors as senotherapeutic / antiaging	Very low	Preclinical + mechanistic only; no human antiaging RCT	Only in research	[7]
NAD+ precursors, rapalogs, senolytics for healthspan	Very low	Preclinical/early-phase; mixed or absent human outcome data	Only in research	[10], [11]

GRADE domain notes. Kidney/CV drug evidence has low risk of bias, low heterogeneity, and direct outcomes (kidney failure, MACE, death). Indirectness is the main limitation for longevity practice: trials enrolled higher-risk populations (established CKD, T2D, CVD, obesity), so extrapolation to low-risk, younger “optimisation” clients is uncertain. Geroprotective claims are downgraded for indirectness (surrogate/biomarker endpoints), imprecision and probable publication/confounding bias.

4. Patient selection and indications

Who may benefit (case-finding and staging for all adult clients).

– Routine CKM staging with BMI, waist circumference, BP, lipids, glycaemia, and eGFR + UACR is reasonable in all adult clients, with frequency escalating by stage.[1]

– Highest-yield candidates for pharmacological intensification: middle-aged adults with clustered cardiometabolic risk (central obesity, hypertension, dysglycaemia, atherogenic dyslipidaemia); anyone with CKD (eGFR <60 or UACR ≥30 mg/g); T2D or prediabetes; established or subclinical ASCVD; PREVENT 10-year CVD risk ≥7.5% to prioritise pharmacotherapy.[1]

– Older adults with frailty: benefit from risk-factor control but require individualised targets and caution with polypharmacy and hypotension/hyperkalaemia.

– Athletic/low-risk clients seeking optimisation: lifestyle measures apply; pharmacotherapy for hard outcomes is generally not indicated at low absolute risk and would be off-label/experimental.

Baseline thresholds triggering guideline-directed drug therapy (regardless of predicted risk): HbA1c above target in diabetes; persistent albuminuria in CKD (RAS inhibitor + SGLT2 inhibitor); stage 2 hypertension or ≥140/90 mmHg; LDL-C ≥190 mg/dL (≥4.9 mmol/L).[21]

Exclusion / high-risk groups requiring specialist input:

– eGFR <20–25 mL/min/1.73 m² (drug-specific initiation thresholds below), advanced CKD G4–G5 and dialysis (limited evidence, specialist domain).[1]

– Serum potassium >5.0 mmol/L before MRA initiation.[22]

– Pregnancy/breastfeeding (RAS inhibitors, SGLT2 inhibitors, GLP-1 RAs, finerenone, statins contraindicated or unadvised).

– History of medullary thyroid carcinoma/MEN2, pancreatitis (caution with GLP-1 RAs).[12]

Regulatory/ethical status (UK).

– On-label: SGLT2 inhibitors, GLP-1 RAs, finerenone, RAS inhibitors and statins used within their MHRA/NICE-approved indications (CKD, T2D, HF, obesity, CVD prevention).

– Off-label: use of these agents purely for “longevity”/healthspan in low-risk clients without a licensed indication — permissible only as adjunctive care with explicit informed consent and documentation.

– Only in research: metformin, rapalogs, NAD+ precursors and senolytics for antiaging/healthspan should ideally be confined to trials/registries (e.g. TAME, VA-IMPACT).[10][20]

5. Assessment and baseline work-up

History and examination. Cardiometabolic and family history; nephrotoxin/medication review (NSAIDs, lithium, calcineurin inhibitors); smoking, alcohol, sleep (screen for OSA where indicated); social determinants of health; anthropometry (BMI + waist circumference; consider lower BMI thresholds in South Asian and East Asian clients); seated BP with correct technique.[23][1]

Baseline investigations (CKM-tailored):

– Kidney: eGFR (creatinine; confirm with cystatin C where available) AND UACR — both required to diagnose/stage CKD.[1][24]

– Metabolic: fasting glucose and HbA1c; fasting lipid panel including triglycerides and HDL-C; consider non-HDL-C or apolipoprotein B if hypertriglyceridaemic.[1]

– Adiposity/liver: liver enzymes and non-invasive fibrosis assessment (e.g. FIB-4) where MASLD is suspected.[1]

– Potassium and bicarbonate (baseline before RAS inhibitor/MRA).[22]

– Consider CAC scoring in intermediate-risk clients to refine ASCVD risk and LDL-C goals (stage 3).[1]

Risk stratification.

– Quantify 10- and 30-year risk with the PREVENT equations; ≥20% 10-year CVD risk defines a stage 3 criterion, ≥7.5% prioritises pharmacotherapy.[1]

– Stratify kidney risk with the KDIGO eGFR/UACR “heat map”; consider the Kidney Failure Risk Equation for referral discussions.[17]

– Stratify harm risk: baseline potassium, eGFR, volume status, hypoglycaemia risk, frailty.

Baseline documentation for meaningful follow-up. CKM stage; BMI, waist circumference, BP; eGFR, UACR, potassium; HbA1c, lipids; PREVENT score; medication list; shared-decision-making/consent record (especially for any off-label use). Validated ageing biomarkers (e.g. epigenetic clocks) may be recorded but should be framed as research surrogates, not decision-making endpoints, as their linkage to hard outcomes is not established.

6. Dosing regimens and practical implementation

Robust human-data regimens (guideline-directed; on-label for stated indications).

– RAS inhibitors (ACEi/ARB): first-line in CKD with albuminuria or hypertension; initiate at eGFR ≥30 mL/min/1.73 m²; titrate to maximum tolerated/antihypertensive dose; do not routinely stop in advancing CKD (STOP-ACEi) unless severe hyperkalaemia.[4][1]

– SGLT2 inhibitors (e.g. dapagliflozin 10 mg od, empagliflozin 10 mg od): initiate at eGFR ≥20 mL/min/1.73 m²; may continue to kidney failure; no titration; anticipate and do not react to the early protective eGFR dip.[4][25][1]

– GLP-1 / incretin-based therapy (e.g. semaglutide, tirzepatide): slow dose escalation to mitigate GI effects; used for obesity, T2D, and MACE reduction in indicated populations; note high real-world discontinuation (up to ~50% at 1 year).[12][4]

– Non-steroidal MRA (finerenone): for CKD + T2D with persistent albuminuria on RAS inhibitor ± SGLT2 inhibitor; initiate at eGFR ≥25 mL/min/1.73 m² only if potassium ≤4.8–5.0 mmol/L; typical 10 or 20 mg od by eGFR/potassium; withhold if potassium >5.5 and restart at 10 mg once ≤5.0.[22][26][1]

– Lipid-lowering therapy: high-intensity statin ± ezetimibe; add PCSK9 inhibitor, inclisiran or bempedoic acid to reach LDL-C targets by stage (e.g. <55 mg/dL / <1.4 mmol/L in stage 4 or very-high-risk).[1]

Non-pharmacological protocols (robust or moderate human data).

– Physical activity: target ≥150 min/week moderate-intensity; individualise by comorbidity/functional status.[17]

– Weight loss: structured lifestyle intervention aiming ≥5–10% loss; ≥15% (typically surgical/pharmacological) more consistently linked to mortality benefit.[27][13]

– Diet: DASH or Mediterranean pattern; sodium <2.3 g/day; higher plant-based protein and complex carbohydrate/fibre; avoid excessive protein restriction in frailty-prone clients.[17][1]

– Smoking cessation for all.[17]

Regimens requiring caution (extrapolated / early-phase / research only).

– SGLT2 inhibitors or metformin prescribed to normoglycaemic, low-risk clients for “antiaging”: no hard-outcome human evidence; off-label; only within a research/consent framework.[7][20]

– Rapalogs, NAD+ precursors, senolytic combinations: dosing not established for healthspan; confine to trials.[10][11]

7. Monitoring, safety and follow-up

Monitoring plan.

– Clinical: weight/waist, BP each visit, volume status, symptoms of hypotension/dehydration, GI tolerance (GLP-1 RAs).

– Laboratory: eGFR, UACR, potassium; HbA1c/glucose; lipids; liver panel where relevant.[1]

– After starting/up-titrating RAS inhibitor or MRA, or adding SGLT2 inhibitor: recheck potassium and eGFR (e.g. within 1–4 weeks for MRA/RAS inhibitor). CONFIDENCE showed adding an SGLT2 inhibitor does not eliminate finerenone-associated hyperkalaemia risk, so continued monitoring is required.[28]

Suggested intervals (stage-dependent).

– Stage 0: metabolic + kidney assessment every ~5 years (aligned with lipid screening); BP per age.

– Stage 1: every 2–3 years.

– Stage 2+: at least annually with dual eGFR + UACR.[1]

– After drug initiation/titration: short-term (2–4 weeks for potassium/eGFR), then medium-term (3 months) and long-term (6–12 monthly) when stable.

Adverse effects.

– SGLT2 inhibitors: genital mycotic infections (common), volume depletion, rare euglycaemic DKA; expected early eGFR dip.[4]

– GLP-1 RAs: nausea/vomiting/diarrhoea common driving discontinuation (~12.7% in trials); no significant excess of pancreatitis, medullary thyroid cancer or severe hypoglycaemia vs placebo in meta-analysis.[12]

– Finerenone: ≥mild hyperkalaemia ~14–21% vs ~8–9% placebo; hospitalisation for hyperkalaemia uncommon (~0.9%), no fatal events in pooled analysis; risk higher with diabetes, lower eGFR, higher UACR, beta-blocker use; reduced by diuretics/SGLT2 inhibitors.[6][26]

– RAS inhibitors: hyperkalaemia, functional eGFR decline, cough (ACEi), angio-oedema.

– Statins: myalgia, transaminitis.

Actions for abnormal findings. Potassium >5.5 mmol/L: withhold MRA (restart at lower dose once ≤5.0), review RAS inhibitor and dietary potassium, consider potassium binder. Sustained eGFR fall >30% beyond expected SGLT2 dip or refractory hyperkalaemia: reassess, reduce/stop offending agent, refer nephrology. Persistent albuminuria despite optimised RAS inhibitor + SGLT2 inhibitor: add finerenone or GLP-1 RA (if T2D).[1]

Interactions. Combining RAS inhibitor + MRA raises hyperkalaemia risk; NSAIDs reduce efficacy and add nephrotoxicity; caution combining multiple BP-lowering/volume-depleting agents in frail or dehydrated clients. SGLT2 inhibitor + GLP-1 RA appear to give independent, additive cardiorenal benefit without interaction.[5]

Special populations. Pregnancy/breastfeeding: avoid RAS inhibitors, SGLT2 inhibitors, GLP-1 RAs, finerenone, statins. Renal impairment: observe drug-specific eGFR thresholds; advanced CKD G4–G5 and dialysis — evidence limited, specialist-led.[1] Frailty/extremes of age: individualise BP and glycaemic targets; targets in eGFR <15 rely on clinical judgement and shared decision-making.[1]

8. Contraindications and cautions

Absolute contraindications.

– Pregnancy/breastfeeding for RAS inhibitors, SGLT2 inhibitors, GLP-1 RAs, finerenone and statins.

– Finerenone: concurrent strong CYP3A4 inhibitors; hyperkalaemia; (per label) adrenal insufficiency.

– GLP-1 RAs: personal/family history of medullary thyroid carcinoma or MEN2.

Relative contraindications / specialist advice.

– eGFR below drug-specific initiation thresholds (RAS inhibitor <30, SGLT2 inhibitor <20, finerenone <25 mL/min/1.73 m²).[1]

– Baseline potassium >5.0 mmol/L (MRA/RAS inhibitor).[22]

– Recurrent volume depletion, recurrent genital infection or prior euglycaemic DKA (SGLT2 inhibitors); prior pancreatitis or significant gastroparesis (GLP-1 RAs).

Harm likely to outweigh benefit with current evidence.

– Prescribing metformin, SGLT2 inhibitors or other agents to healthy, normoglycaemic, low-risk clients solely for antiaging outside a research framework: unproven benefit, real adverse-event and cost exposure.[7][20]

– Aggressive multi-drug cardiorenal therapy in frail, low-risk older adults where hypotension, AKI and hyperkalaemia risks dominate.

9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors (central obesity, hypertension, prediabetes, UACR 45 mg/g).

– Recommendation: Offer structured CKM management — Strong recommendation (guideline-based).[1]

– Assessment: full CKM staging (likely stage 2), PREVENT score, eGFR + UACR, lipids, HbA1c, potassium.

– Shared decision-making: lifestyle as foundation; explain kidney and CV rationale for RAS inhibitor + SGLT2 inhibitor for albuminuria.

– Initiation: lifestyle (Mediterranean/DASH, ≥150 min/week activity, ≥5–10% weight loss target); RAS inhibitor titrated to max tolerated; add SGLT2 inhibitor (eGFR ≥20); statin per LDL-C/risk targets; GLP-1 RA if obesity/T2D indication met.[1][4]

– Monitoring: potassium/eGFR at 2–4 weeks after RAS inhibitor start; then 3-monthly until stable; annual UACR.

– Escalate/refer: persistent albuminuria despite RAS inhibitor + SGLT2 inhibitor → add finerenone (if T2D) or GLP-1 RA; refer nephrology if eGFR falling or UACR rising.

Scenario B — Older, frail adult with multimorbidity and eGFR 34, potassium 5.1.

– Recommendation: Restrict/individualise — offer high-value, low-harm elements; Conditional recommendation; avoid aggressive polypharmacy.

– Assessment: frailty, falls, orthostatic BP, polypharmacy and nephrotoxin review; confirm potassium and volume status.

– Shared decision-making: prioritise interventions with clear benefit and tolerability; relax BP/glycaemic targets; discuss deprescribing where appropriate.

– Initiation: continue/optimise SGLT2 inhibitor (can continue below eGFR 20 once started) as generally well tolerated; cautious RAS inhibitor if not already on and BP allows; avoid MRA until potassium ≤5.0 and only with close monitoring.[1][22]

– Monitoring: closer potassium/eGFR surveillance; watch hypotension/AKI during intercurrent illness (sick-day rules).

– Escalate/stop: stop offending agent for potassium >5.5 or symptomatic hypotension; nephrology/geriatrics input.

Scenario C — Client already under specialist care (T2D + CKD on RAS inhibitor + SGLT2 inhibitor), seeking longevity optimisation adjunct.

– Recommendation: Consider guideline-directed intensification in coordination with the specialist; Conditional recommendation.[1]

– Assessment: confirm residual albuminuria, potassium, eGFR trajectory, adherence.

– Shared decision-making + consent: coordinate with nephrology/endocrinology (CKM “point person” model); document any off-label element.[1]

– Initiation: add finerenone for persistent albuminuria if potassium/eGFR permit, or GLP-1 RA for weight/CV benefit; intensify LDL-C lowering to target.[1][6]

– Monitoring: potassium/eGFR after finerenone start; harmonise follow-up with specialist.

– Escalate/stop: refractory hyperkalaemia or accelerated eGFR decline → specialist review; do not add experimental antiaging agents outside a trial.

10. Research gaps and future directions

– Low-risk and younger populations: cardiorenal drug trials enrolled higher-risk cohorts; efficacy and net benefit of early “preventive” use in low-risk longevity clients is unproven (indirectness).[12][4]

– GLP-1 RAs and hard kidney endpoints: benefit on kidney failure is moderate-certainty and partly albuminuria-driven; dedicated trials in non-diabetic and CKD-without-obesity populations are needed.[12][4]

– Finerenone beyond T2D: INFINITY supports broader efficacy, but licensed use and long-term safety in non-diabetic CKD require confirmation.[6]

– Combination sequencing: optimal ordering and additive benefit/harm of RAS inhibitor + SGLT2 inhibitor + GLP-1 RA + finerenone quadruple therapy needs prospective study.[5][28]

– Geroprotective agents: metformin (TAME, VA-IMPACT), SGLT2 inhibitors as senotherapeutics, rapalogs, NAD+ precursors and senolytics lack hard-outcome human data; these should remain within well-designed trials or registries.[10][7][20]

– Ageing biomarkers as endpoints: whether epigenetic clocks or other surrogates predict CKM hard outcomes and respond meaningfully to intervention is unestablished; they should not currently drive treatment decisions.

References

1. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Ndumele CE, Rodriguez F, Dixon DL, et al. Journal of the American College of Cardiology. 2026;87(22S):e1889-e2007. doi:10.1016/j.jacc.2026.03.056.
2. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Ndumele CE, Neeland IJ, Tuttle KR, et al. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001186.
3. Cardiovascular-Kidney-Metabolic Syndrome and Life Expectancy in U.S. Adults. Ma N, Zhang XQ, Chou TS, et al. JACC. Advances. 2026;5(4):102664. doi:10.1016/j.jacadv.2026.102664.
4. Chronic Kidney Disease, Complex Conditions, and Advancing Therapeutics: New Hope and Challenges. Lees JS, Škoberne A, Zhang L, et al. Lancet (London, England). 2026;407(10546):2444-2460. doi:10.1016/S0140-6736(26)00653-7.
5. Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Prevention: Evidence From Randomized Outcomes Trials. Gerstein HC, Sattar N. JACC. Advances. 2026;5(4):102645. doi:10.1016/j.jacadv.2026.102645.
6. Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease: An Individual Participant Data Pooled Analysis (INFINITY). Neuen BL, Heerspink HJL, Perkovic V, et al. Lancet (London, England). 2026;407(10546):2375-2386. doi:10.1016/S0140-6736(26)01009-3.
7. Dissecting Out the Unexpected Effects of SGLT2 Inhibitors on Human Aging. Katsuumi G, Minamino T. The Journal of Clinical Endocrinology and Metabolism. 2026;111(8):2154-2165. doi:10.1210/clinem/dgag207.
8. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
9. Metformin Reduces All-Cause Mortality and Diseases of Ageing Independent of Its Effect on Diabetes Control: A Systematic Review and Meta-Analysis. Campbell JM, Bellman SM, Stephenson MD, Lisy K. Ageing Research Reviews. 2017;40:31-44. doi:10.1016/j.arr.2017.08.003.
10. Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. Espinoza SE, Khosla S, Baur JA, de Cabo R, Musi N. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):53-60. doi:10.1093/gerona/glad034.
11. Geroscience. Kritchevsky SB, Cummings SR. JAMA. 2025;334(12):1094-1102. doi:10.1001/jama.2025.11289.
12. Effects of GLP-1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta-Analysis of Randomised Controlled Trials. Badve SV, Bilal A, Lee MMY, et al. The Lancet. Diabetes & Endocrinology. 2025;13(1):15-28. doi:10.1016/S2213-8587(24)00271-7.
13. Effects of Weight Loss Interventions for Adults Who Are Obese on Mortality, Cardiovascular Disease, and Cancer: Systematic Review and Meta-Analysis. Ma C, Avenell A, Bolland M, et al. BMJ (Clinical Research Ed.). 2017;359:j4849. doi:10.1136/bmj.j4849.
14. Intentional Weight Loss and All-Cause Mortality: A Meta-Analysis of Randomized Clinical Trials. Kritchevsky SB, Beavers KM, Miller ME, et al. PloS One. 2015;10(3):e0121993. doi:10.1371/journal.pone.0121993.
15. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018.
16. 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Primary Care Management of Chronic Kidney Disease. Schwartz AR, Sosnov J, Brown J, et al. Annals of Internal Medicine. 2026;179(3):411-424. doi:10.7326/ANNALS-25-03499.
17. Chronic Kidney Disease. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Lancet (London, England). 2021;398(10302):786-802. doi:10.1016/S0140-6736(21)00519-5.
18. Relationship Between Control of Cardiovascular Risk Factors and Chronic Kidney Disease Progression, Cardiovascular Disease Events, And Mortality in Chinese Adults. Geng T, Xu W, Gao H, et al. Journal of the American College of Cardiology. 2024;84(14):1313-1324. doi:10.1016/j.jacc.2024.06.041.
19. SGLT2 Inhibitors and GLP-1 Receptor Agonists: Established and Emerging Indications. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. Lancet (London, England). 2021;398(10296):262-276. doi:10.1016/S0140-6736(21)00536-5.
20. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Lee CG, Heckman-Stoddard B, Dabelea D, et al. Diabetes Care. 2021;44(12):2775-2782. doi:10.2337/dc21-1046.
21. Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. Khan SS, Bhave N, Blumenthal RS, et al. Circulation. 2026;154(4):e159-e180. doi:10.1161/CIR.0000000000001447.
22. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney International. 2022;102(5S):S1-S127. doi:10.1016/j.kint.2022.06.008.
23. Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Mayne KJ, Hanlon P, Lees JS. Diabetes, Obesity & Metabolism. 2024;26 Suppl 6:43-54. doi:10.1111/dom.15625.
24. Chronic Kidney Disease: Prevention, Diagnosis, and Treatment. Goodbred AJ, Langan RC. American Family Physician. 2023;108(6):554-561.
25. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care. 2026;49(Suppl 1):S246-S260. doi:10.2337/dc26-S011.
26. Hyperkalemia Risk With Finerenone: Results From the FIDELIO-DKD Trial. Agarwal R, Joseph A, Anker SD, et al. Journal of the American Society of Nephrology : JASN. 2022;33(1):225-237. doi:10.1681/ASN.2021070942.
27. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients With Obesity. Garvey WT, Mechanick JI, Brett EM, et al. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016;22 Suppl 3:1-203. doi:10.4158/EP161365.GL.
28. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. Agarwal R, Green JB, Heerspink HJL, et al. Journal of the American College of Cardiology. 2026;87(7):772-784. doi:10.1016/j.jacc.2025.10.049.